Reference
|
Disease and Number of Subjects
|
Study Design
|
Monotherapy (Mean Dosage) |
Dosage of Dual Therapy
|
Results of Dual Therapy
|
Comerio et al.
15
|
Hypertension n=13 |
R/D‐B |
Lacidipine 4 mg/d; verapamil 240 mg/d |
Lacidipine 4 mg/d with verapamil 240 mg/d |
Combined lacidipine and verapamil reduced BP from 160±11/101±7 to 140±11/92±5 |
Kiowski et al.
20
|
Hypertension n=8 |
O‐L, cross‐over |
Amlodipine 44.5 µg/min/100 mL of forearm tissue |
Amlodipine 44.5 µg/min/100 mL 2.5 h of forearm tissue with verapamil 40 µg/min/100 mL of forearm tissue |
↑ forearm blood flow (2.9±1.7 to a maximum of 23.6±7.6 mL with amlodipine); further increase to 34.4±9.8 mL/min/100 mL with verapamil |
Andreyev et al.
12
|
Hypertension and stable effort angina n=16 |
O‐L, cross‐over |
Diltiazem 240 mg/d; nitrendipine 20 mg/d |
Diltiazem 120 mg/d with nitrendipine 20 mg/d |
Better BP control compared with diltiazem monotherapy but not nitrendipine monotherapy; better ischemic control with dual therapy |
Nalbantgil et al.
21
|
Hypertension n=40 |
R/P‐C/D‐B, cross‐over |
Verapamil 240 mg/d and nitrendipine 20 mg/d |
Verapamil 120 mg/d with nitrendipine 10 mg/d |
Improved BP control and fewer adverse effects with dual therapy |
Kaesemeyer et al.
17
|
Mild hypertension n=23 |
Retrospective analysis |
|
Verapamil 120–360 mg/d with nifedipine 30–90 mg/d |
BP controlled in 100% (23/23) and leg edema in 30% (7/23) |
Kaesemeyer et al.
17
|
Moderate to severe hypertension n=27 |
Retrospective analysis |
|
Verapamil 120–480 mg/d with nifedipine 180 mg/d or verapamil 480 mg/d with nifedipine 30–180 mg/d |
BP controlled in 89% (24/27) and leg edema in 26% (7/27) |
Saseen et al.
18
|
Hypertension n=16 |
R/D‐B, three‐period crossover |
Nifedipine‐SR 30 mg/d |
Nifedipine‐SR 30 mg/d with either diltiazem‐SR 180 mg/d or verapamil‐SR 180 mg/d; cross‐over to diltiazem or verapamil |
Both combinations ↓ systolic and diastolic BP more than nifedipine alone; verapamil and diltiazem ↑ nifedipine plasma concentrations by 49% and 21%, respectively; 50% of subjects with constipation in the nifedipine and verapamil group |
R=randomized; D‐B=double‐blind; O‐L=open‐label; P‐C=placebo‐controlled; BP=blood pressure; SR=sustained release
Adapted with permission from Ann Pharmacother. 1996;30:802–810.
16
|